Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Pomalidomide was approved on February 8
42(4):505-520
Inhibiting the SAC could represent a promising new approach to selectively target cancer cells
Src and Abl are protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells
Doxazosin rasugrel (Maleic acid) Pomalidomide was approved on FebruaryDoxazosin is an 1 adrenergic receptor blocker that inhibits the binding of norepinephrine, which is released from sympathetic nerve terminals, to the 1 receptors on the membrane of vascular smooth muscle cells. Blockages of the alpha 1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha 1c adrenoceptor, the predominant functional type in
US$ 69.00
US$ 119.00
US$ 38.00
US$ 79.00
US$ 38.00
US$ 362.25
US$ 52.00
US$ 178.83
US$ 1002.60
US$ 237.78